Welcome to our dedicated page for Wave Life Sciences Ltd. SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Wave Life Sciences Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Wave Life Sciences Ltd.'s regulatory disclosures and financial reporting.
Wave Life Sciences reported positive interim Phase 1 data from its INLIGHT trial of WVE-007, an investigational INHBE GalNAc-siRNA for people living with overweight or obesity. After six months, a single 240 mg dose produced placebo-adjusted reductions in visceral fat of -14%, total fat of -5%, waist circumference of -3%, and body weight of -1%, while lean mass increased by +2%. WVE-007 showed durable, dose-dependent suppression of serum Activin E for at least seven months, supporting the potential for once or twice-yearly dosing, and was generally safe and well tolerated up to 600 mg, with only mild or moderate adverse events.
Wave Life Sciences Ltd. officer Francis Chris reported option exercises and share sales in Wave Life Sciences ordinary shares. On February 26, 2026, he exercised two share options for 17,900 and 15,294 shares at exercise prices of $3.87 and $4.75 per share, respectively, receiving the corresponding ordinary shares. He then sold 17,900 shares at a weighted-average price of $15.094 per share and 15,294 shares at $15.00 per share in open-market transactions. The filing notes these transactions were carried out under a pre-established Rule 10b5‑1 trading plan, and after the reported trades he held 61,867 ordinary shares directly.
Wave Life Sciences Ltd. provides an annual overview of its business, pipeline and risks as a clinical-stage RNA medicines company. The company focuses on obesity, alpha-1 antitrypsin deficiency (AATD), PNPLA3 I148M liver disease, Duchenne muscular dystrophy and Huntington’s disease using its PRISM chemistry platform.
Lead programs include WVE-007 for obesity, WVE-006 for AATD and WVE-008 for PNPLA3 I148M liver disease, alongside WVE-N531 for DMD and WVE-003 for allele-selective Huntington’s disease. As of June 30, 2025, the aggregate market value of non-affiliate shares was $851,013,538, and ordinary shares outstanding were 188,254,954 as of February 19, 2026.
Wave Life Sciences reported much higher cash and a larger loss for 2025 while outlining ambitious RNA programs in obesity, liver and lung disease. Cash and cash equivalents rose to $602.1 million as of December 31, 2025, giving an expected cash runway into Q3 2028.
Full-year 2025 revenue was $42.7 million, down from $108.3 million in 2024, as collaboration revenue declined. Research and development expenses increased to $182.8 million and general and administrative to $75.3 million, driving a net loss of $204.4 million versus a $97.0 million loss in 2024.
The company highlighted WVE-007 for obesity, where a single dose showed fat loss similar to GLP‑1 drugs at three months while preserving lean mass, with data updates and a Phase 2a multidose trial planned in 2026. It also advanced WVE‑006 for alpha‑1 antitrypsin deficiency, achieving total AAT levels above 11 micromolar and dynamic increases during acute phase responses, and plans a 2026 clinical trial application for WVE‑008 in PNPLA3 I148M liver disease.
Wave Life Sciences Ltd. received an updated ownership report from Adage Capital Management, L.P. and principals Robert Atchinson and Phillip Gross. The reporting group states beneficial ownership of 9,786,061 ordinary shares, representing 5.35% of the class as of the event date.
All 9,786,061 shares are reported with shared voting and shared dispositive power, and no shares with sole power. The percentage is based on a total of 182,971,259 ordinary shares outstanding, which combines 167,181,784 shares outstanding as of November 7, 2025 and 15,789,475 shares offered under a December 11, 2025 prospectus. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Wave Life Sciences’ Chief Financial Officer Kyle Moran reported routine equity compensation and a related tax sale. On February 5, 2026, he received 45,625 restricted share units that vest in four equal annual installments from February 8, 2027 through February 8, 2030, and a share option for 273,750 ordinary shares at an exercise price of $12.75 per share, vesting 25% on February 8, 2027 and 6.25% quarterly thereafter until February 8, 2030. Following these grants, he held 137,973 ordinary shares and 273,750 options directly. On February 9, 2026, he sold 3,588 ordinary shares at $13.45 per share to cover taxes triggered by RSU vesting under an automatic sale provision, leaving 134,385 ordinary shares owned directly.
Wave Life Sciences Ltd. insider activity: President and CEO Paul Bolno received 165,000 restricted share units on February 5, 2026, bringing his direct holdings to 286,000 ordinary shares. These RSUs vest in four equal annual installments from February 8, 2027 through February 8, 2030.
On February 9, 2026, he sold 10,480 ordinary shares at $13.45 each solely to cover taxes from RSU vesting, leaving 275,520 shares owned directly. He also received a stock option for 1,000,000 ordinary shares at a $12.75 exercise price, vesting 25% on February 8, 2027 and 6.25% quarterly until February 8, 2030.
Wave Life Sciences (WVE) executive Chris Francis reported equity compensation grants and a small tax-related share sale. On February 5, 2026, he received 38,750 restricted share units that vest in four equal annual installments from February 8, 2027 through February 8, 2030, and a share option for 232,500 ordinary shares at an exercise price of $12.75 per share, vesting 25% on February 8, 2027 and 6.25% quarterly until February 8, 2030. On February 9, 2026, he sold 1,883 ordinary shares at $13.45 per share solely to cover taxes from RSU vesting, leaving 61,867 ordinary shares held directly.
Wave Life Sciences Ltd. executive Chandra Vargeese reported new equity awards and a small share sale. On February 5, 2026, Vargeese acquired 45,625 restricted share units, which vest in four annual 25% installments from February 8, 2027 through February 8, 2030. The same day, Vargeese received a stock option for 273,750 ordinary shares at an exercise price of $12.75, vesting 25% on February 8, 2027 and an additional 6.25% quarterly until February 8, 2030. On February 9, 2026, Vargeese sold 3,228 ordinary shares at $13.45 per share solely to cover taxes related to RSU vesting, as required under the RSU agreement. After these transactions, Vargeese directly held 408,246 ordinary shares and 273,750 options.
Kyle Moran filed a notice of proposed sale for 3,564 ordinary shares of WVE, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ around 02/09/2026, with an aggregate market value of $47,935.80. These shares were acquired via restricted stock unit vesting on 02/08/2026 as equity compensation.
During the prior three months, Kyle Moran sold 210,000 ordinary shares on 12/08/2025 for gross proceeds of $3,102,000.00 and 86,000 ordinary shares on 12/09/2025 for gross proceeds of $1,730,250.00. Ordinary shares outstanding were 187,693,059 at the time of the planned sale.